Arthropathy News and Research

RSS

IL-17: The molecule that could revolutionize autoimmune and cancer treatments

The research paper explores the multifaceted role of the IL-17 family in immune response, covering everything from infection control to pathological conditions like autoimmune diseases and cancer. Future therapies may exploit IL-17's unique signaling pathways to offer more targeted and cost-effective treatments.

12 Oct 2023

AI interpretations of MRI images could provide more accurate RA prediction

Early inflammatory arthritis is often undifferentiated, but it may develop into established RA or another arthropathy.

31 May 2023

Study identifies several proteins that protect against disease development

Inflammatory processes are associated with a large range of human diseases, including rheumatic diseases and allergies. Protein biomarkers are measurable molecules that can have a prognostic value in patients, be used to diagnose disease, or indicate severity of disease.

8 Dec 2021

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

Excess coffee consumption can cause poor health

Cappuccino, latte or short black, coffee is one of the most commonly consumed drinks in the world. But whether it's good or bad for your health can be clarified by genetics, as a world-first study from the University of South Australia's Australian Centre for Precision Health shows that excess coffee consumption can cause poor health.

13 May 2020

Optimal therapy for Down syndrome arthropathy remains unclear, reveals study

A new study found that patients with Down syndrome arthropathy continue to have an approximate year-long delay in diagnosis from the onset of their symptoms, and that optimal therapy for this condition remains unclear.

11 Nov 2019

Children with Down syndrome at greater risk of an associated form of arthritis

A new study finds that children with Down syndrome are at an increased risk of an associated form of arthritis.

10 Nov 2019

Researchers identify risk factors for severe infection after knee replacement

In the largest study of its kind, researchers from the Musculoskeletal Research Unit at the University of Bristol have identified the most important risk factors for developing severe infection after knee replacement.

17 Apr 2019

Loyola Medicine study finds high success rate for diabetic Charcot foot surgery

Nearly four out of five diabetic patients with severe cases of a disabling condition called Charcot foot were able to walk normally again following surgery, a Loyola Medicine study has found.

14 Dec 2017

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Early gains in pain relief, behavioral markers and function were not sustained in patients treated with platelet-rich plasma (PRP) injection for facet joint arthropathy, new research shows. Results were available at the 31st Annual Meeting of the American Academy of Pain Medicine.

25 Mar 2015

Study compares HA injections and triamcinolone in improving pain in patients with lumbar ZJT arthropathy

A study presented at AAP 2015 San Antonio compares the effectiveness of HA injections to triamcinolone in improving pain and function in patients with lumbar ZJT arthropathy.

13 Mar 2015

Researchers set up innovative project to monitor physical activity of patients with haemophilia

The research group Intelligent Data Analysis Laboratory from the School of Engineering Universitat de València (UV) and a team of scientists at the Faculty of Physiotherapy led by Professor Felipe Querol have set up an innovative project for monitoring the physical activity of people with haemophilia through individual devices with the purpose of developing patterns which help to improve their quality of life and treatments.

26 Nov 2014

Opioid use does not impair reverse shoulder arthroplasty success

Taking opioids prior to reverse shoulder arthroplasty does not hamper patients’ chances of having successful outcomes, researchers have found.

28 Jul 2014

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency).

27 May 2014

Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Using cholesterol-lowering statins may be associated with musculoskeletal conditions, arthropathies (joint diseases) and injuries, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

4 Jun 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Sun exposure advice recommended for anti-TNF users

Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.

2 Jul 2012

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.

From Baxter International Inc. 5 Jun 2012

Arthropathy News and Research

IL-17: The molecule that could revolutionize autoimmune and cancer treatments

AI interpretations of MRI images could provide more accurate RA prediction

Study identifies several proteins that protect against disease development

Providing personalized care for bleeding disorders

Providing personalized care for bleeding disorders

Excess coffee consumption can cause poor health

Optimal therapy for Down syndrome arthropathy remains unclear, reveals study

Children with Down syndrome at greater risk of an associated form of arthritis

Researchers identify risk factors for severe infection after knee replacement

Loyola Medicine study finds high success rate for diabetic Charcot foot surgery

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Study: Early improvements not sustained in patients treated with PRP injection for facet joint arthropathy

Study compares HA injections and triamcinolone in improving pain in patients with lumbar ZJT arthropathy

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Opioid use does not impair reverse shoulder arthroplasty success

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Sun exposure advice recommended for anti-TNF users

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News